Tranexamic Acid Administration in Continuous Bladder Irrigation for Hematuria
Add 1000 mg of tranexamic acid directly into the bladder via the Foley catheter, allow it to dwell for 15 minutes with the catheter clamped, then declamp and initiate continuous bladder irrigation. This intravesical approach has demonstrated significant reductions in bleeding duration, irrigation requirements, and emergency department length of stay 1.
Administration Protocol
Intravesical (Direct Bladder) Administration
- Dose: 1000 mg tranexamic acid
- Route: Inject through the 3-way Foley catheter directly into the bladder
- Dwell time: Clamp catheter for 15 minutes after injection
- Then: Declamp and begin standard CBI with normal saline
This method resulted in:
- Median ED length of stay reduced from 411 to 274 minutes (p < 0.001)
- Foley catheter duration decreased from 308 to 145 minutes (p < 0.001)
- Revisit rates dropped from 12.3% to 2.3% (p = 0.031) 1
Alternative: TXA in Irrigation Fluid
For surgical cases (particularly percutaneous nephrolithotomy), 0.1% tranexamic acid concentration in the irrigant solution is effective:
- Significantly reduces perioperative blood loss (154.55 vs 212.61 mL, p < 0.0001)
- Decreases transfusion requirements (5% vs 12.5%, p = 0.012)
- Lowers complication rates (19% vs 28%, p = 0.044) 2
Pharmacologic Considerations from FDA Labeling
Standard IV dosing (for reference, though intravesical is preferred for CBI):
- 1 g IV over 10 minutes (at 1 mL/min)
- Second dose of 1 g if bleeding continues after 30 minutes 3
- Terminal half-life: approximately 11 hours
95% excreted unchanged in urine 3
Critical Safety Parameters
Renal Function Adjustment Required
Dose reduction is mandatory in renal impairment since TXA is eliminated via glomerular filtration:
- Serum creatinine 1.4-2.8 mg/dL: 51% urinary excretion at 24 hours
- Serum creatinine 2.8-5.7 mg/dL: 39% urinary excretion
- Serum creatinine >5.7 mg/dL: 19% urinary excretion 3
Contraindications and Warnings
- Do NOT use in patients on all-trans retinoic acid (tretinoin) - 3 of 4 patients died from thrombotic complications in one series 3
- Monitor for thromboembolic events, though none were reported in recent urologic series 4
- No evidence of increased renal failure risk from urinary clots in systematic review of 342 patients 5
Evidence Quality Assessment
The intravesical approach 1 represents the most practical and effective method for emergency department hematuria management, with a 2023 publication date making it the most current evidence. The before-and-after study design (N=159 patients) showed consistent benefits across multiple clinically relevant endpoints.
The 0.1% irrigation concentration 2 is better suited for intraoperative use during urologic procedures (2017 RCT, N=400), where it can be continuously administered throughout the case.
Common Pitfalls to Avoid
- Don't add TXA to CBI bags for continuous infusion in non-surgical hematuria - the single intravesical bolus with dwell time is more effective and evidence-based
- Don't skip the 15-minute dwell time - this allows local tissue penetration and antifibrinolytic effect
- Don't forget renal dose adjustment - standard dosing in renal impairment risks accumulation
- Don't use in patients with history of thromboembolic disease without careful risk-benefit analysis
The mechanism involves saturating plasminogen's high-affinity lysine binding sites (Kd = 1.1 µmol/L), preventing fibrin matrix dissolution while preserving hemostatic clot structure 3.